What's Your Problem‪?‬ Pushkin

Last year, the FDA approved a treatment for sickle cell disease using a revolutionary new gene editing technology called CRISPR. Rachel Haurwitz conducted pioneering research on CRISPR as a graduate student. Now she’s the co-founder and CEO of Caribou Biosciences. Rachel's problem is this: How can you improve CRISPR and use it to engineer human immune cells to fight cancer? 
See omnystudio.com/listener for privacy information.

Robert Langer has co-founded dozens of companies, holds over a thousand patents, and is a pioneering figure in drug delivery and tissue engineering. Robert has solved a lot of problems, and is working on many more with his lab at MIT. But there is one big problem that has stuck with Robert his whole career: How do you get discoveries out of the lab and into the world?
See omnystudio.com/listener for privacy information.

Mateo Jaramillo is the co-founder and CEO of Form Energy. Mateo’s problem is this: How do you build batteries that can provide affordable backup power to the grid for days at a time? As it turns out, the basic technology was developed – and then mostly ignored – over 50 years ago.
See omnystudio.com/listener for privacy information.

This March, doctors successfully transplanted a pig kidney into a person for the first time in history. Mike Curtis is the CEO of eGenesis, the company that raised the pig whose kidney was used for the procedure. Mike's problem is this: How do you genetically engineer pigs to provide organs – kidneys, hearts, livers – for people?
See omnystudio.com/listener for privacy information.

Imagine picking up your phone and ordering something from Walmart. Fifteen minutes later, a drone hovers over your yard, lowers your order down to you, and zips away. Adam Woodworth wants this to be so boring you don't even notice. He’s the CEO of Wing, a drone delivery company. His problem is this: How do you turn a flashy idea like a delivery drone into something as ubiquitous as a shopping cart?
See omnystudio.com/listener for privacy information.

Psychedelics are going mainstream. The FDA has approved ketamine for certain patients with depression, and may soon approve MDMA for post-traumatic stress disorder (PTSD). But a fundamental question remains unclear: How do psychedelics work?

Gul Dolen is a professor of psychology and neuroscience at UC Berkeley. In a series of experiments, Gul has found evidence of a common mechanism that a wide range of psychedelics use to affect the brain. If Gul is correct, these drugs may be useful not only for people suffering from mental illness, but also for people dealing with neurological problems like strokes.
See omnystudio.com/listener for privacy information.